Keywords: Cellectis. iPS Academia Japan, Regemerative medicine, First-half 2010 results
France’s Cellectis in-licenses technology from iPS Academia Japan; posts first half results
Article | 19 October 2010
French genome engineering specialist Cellectis (Alternext: ALCLS) and iPS Academia Japan have signed two separate non-exclusive agreements granting the Paris-based ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
